Jeffrey Dean Isaacson,Mical Raponi,James Ranger-Moore,Eric L. Powell
申请号：
US13565380
公开号：
US20130116209A1
申请日:
2012.08.02
申请国别(地区):
US
年份:
2013
代理人:
摘要：
The subject invention relates to determining the presence and level of hENT1 expression in tumor tissue that is appropriate for gemcitabine therapy, and more importantly, the level of hENT1 expression that signifies that treatment with a gemcitabine derivative is a more appropriate strategy.
